Down-modulation of survivin expression and inhibition of tumor growth in vivo by EZN-3042, a locked nucleic acid antisense oligonucleotide

Nucleosides, Nucleotides and Nucleic Acids

Volumn 29, Issue 2, 2010, Pages 97-112

  Sapra, Puja ^a   Wang, Maoliang ^a   Bandaru, Raj ^a   Zhao, Hong ^a   Greenberger, Lee M ^a   Horak, Ivan D ^a  

^a Enzon Incorporated   (United States)

Author keywords

Antisense; Liver regeneration; Locked nucleic acid; MRNA; Oligonucleotide; Survivin

Indexed keywords

ANTISENSE OLIGONUCLEOTIDE; EZN 3042; LOCKED NUCLEIC ACID; MESSENGER RNA; PACLITAXEL; SURVIVIN; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BIRC5 PROTEIN, HUMAN; INHIBITOR OF APOPTOSIS PROTEIN; MICROTUBULE ASSOCIATED PROTEIN; OLIGONUCLEOTIDE;

ANAPLASTIC CARCINOMA; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTISENSE THERAPY; APOPTOSIS; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CANCER INHIBITION; CONTINUOUS INFUSION; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; HUMAN; HUMAN CELL; IN VIVO CULTURE; LIVER REGENERATION; LUNG ADENOCARCINOMA; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PROTEIN EXPRESSION; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CELL PROLIFERATION; DISEASE MODEL; DRUG EFFECTS; DRUG SCREENING; FEMALE; GENE EXPRESSION REGULATION; GENETICS; LUNG NEOPLASMS; METABOLISM; NUDE MOUSE; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE;

ANIMALIA;

ANIMALS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; DOWN-REGULATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INHIBITOR OF APOPTOSIS PROTEINS; LIVER REGENERATION; LUNG NEOPLASMS; MAXIMUM TOLERATED DOSE; MICE; MICE, INBRED BALB C; MICE, NUDE; MICROTUBULE-ASSOCIATED PROTEINS; OLIGONUCLEOTIDES; OLIGONUCLEOTIDES, ANTISENSE; PACLITAXEL; RNA, MESSENGER; TREATMENT OUTCOME; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 77949563626     PISSN: 15257770     EISSN: 15322335     Source Type: Journal    
DOI: 10.1080/15257771003597733     Document Type: Article

References (52)

1. Li, F.; Ambrosini, G.; Chu, E.Y.; Plescia, J.; Tognin, S.; et al. Control of apoptosis and mitotic spindle checkpoint by survivin. Nature. 1998, 396, 580-584.
2. Altieri, D.C. Survivin, cancer networks and pathway-directed drug discovery. Nat. Rev. Cancer 2008, 8, 61-70.
3. Mita, A.C.; Mita, M.M.; Nawrocki, S.T.; Giles, F.J. Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics. Clin. Cancer Res. 2008, 14, 5000-5005.
4. Kishi, H.; Igawa, M.; Kikuno, N.; Yoshino, T.; Urakami, S.; et al. Expression of the survivin gene in prostate cancer: correlation with clinicopathological characteristics, proliferative activity and apoptosis. J. Urol. 2004, 171, 1855-1860.
5. Monźo, M.; Rosell, R.; Felip, E.; Astudillo, J.; Śanchez, J.J.; et al. A novel anti-apoptosis gene: reexpression of survivin messenger RNA as a prognosis marker in non?small-cell lung cancers. J. Clin. Oncol. 1999, 17, 2100-2104.
6. Tanaka, K.; Iwamoto, S.; Gon, G.; Nohara, T.; Iwamoto, M.; et al. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin. Cancer Res. 2000, 6, 127-134.
7. Kawasaki, H.; Altieri, D.C.; Lu, C.D.; Toyoda, M.; Tenjo, T.; et al. Inhibition of apoptosis by survivin predicts shorter survival rates in colorectal cancer. Cancer Res. 1998, 58, 5071-5074.
8. Lu,C.D.; Altieri, D.C.; Tanigawa,N. Expression of a novel antiapoptosis gene, survivin, correlated with tumor cell apoptosis and p53 accumulation in gastric carcinomas. Cancer Res. 1998, 58, 1808-1812.
9. Wang, T.T.; Qian, X.P.; Liu, B.R. Survivin: potential role in diagnosis, prognosis and targeted therapy of gastric cancer. World J. Gastroenterol. 2007, 13, 2784-2790.
10. Satoh, K.; Kaneko, K.; Hirota, M.; Masamune, A.; Satoh, A.; et al. Expression of survivin is correlated with cancer cell apoptosis and is involved in the development of human pancreatic duct cell tumors. Cancer 2001, 92, 271-278.
11. Ikeguchi, M.; Ueda, T.; Sakatani, T.; Hirooka, Y.; Kaibara, N. Expression of survivin messenger RNA correlates with poor prognosis in patients with hepatocellular carcinoma. Diagn. Mo.l Pathol. 2002, 11, 33-40.
12. Saitoh, Y.; Yaginuma, Y.; Ishikawa, M. Analysis of Bcl-2, bax and survivin genes in uterine cancer. Int. J. Oncol. 1999, 15, 137-141.
13. Yoshida, H.; Ishiko, O.; Sumi, T.; Matsumoto, Y.; Ogita, S. Survivin, bcl-2 and matrix metalloproteinase-2 enhance progression of clear cell- and serous-type ovarian carcinomas. Int. J. Oncol. 2001, 19, 537-542.
14. Takai, N.; Miyazaki, T.; Nishida, M.; Nasu, K.; Miyakawa, I. Expression of survivin is associated with malignant potential in epithelial ovarian carcinoma. Int. J. Mol. Med. 2002, 10, 211-216.
15. Ambrosini, G.; Adida, C.; Altieri, D.C. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat. Med. 1997, 3, 917-921.
16. Xing, Z.; Conway, E.M.; Kang, C.; Winoto, A. Essential role of survivin, an inhibitor of apoptosis protein, in T cell development, maturation, and homeostasis. J. Exp. Med. 2004, 199, 69-80.
17. Zhang, T.; Otevrel, T.; Gao, Z.; Ehrlich, S.M.; Fields, J.Z.; et al. Evidence that APC regulates survivin expression: a possible mechanism contributing to the stem cell origin of colon cancer. Cancer Res. 2001, 62, 8664-8667.
18. Fukuda, S.; Pelus, L.M. Regulation of the inhibitor-of-apoptosis family member survivin in normal cord blood and bonemarrow CD34(+) cells by hematopoietic growth factors: implication of survivin expression in normal hematopoiesis. Blood 2001, 98, 2091-2100.
19. Gianani, R.; Jarboe, E.; Orlicky, D.; Frost, M.; Bobak, J.; et al. Expression of survivin in normal, hyperplastic, and neoplastic colonic mucosa. Hum. Pathol. 2001, 32, 119-125.
20. Altieri, D.C. The molecular basis and potential role of survivin in cancer diagnosis and therapy. Trends Mol. Med. 2001, 7, 542-547.
21. Kamihira, S.; Yamada, Y.; Hirakata, Y.; Tomonaga, M.; Sugahara, K.; et al. Aberrant expression of caspase cascade regulatory genes in adult T-cell leukaemia: survivin is an important determinant for prognosis. Br. J. Haematol. 2001, 114, 63-69.
22. Adida, C.; Berrebi, D.; Peuchmaur, M.; Reyes-Mugica, M.; Altieri, D.C. Anti-apoptosis gene, survivin, and prognosis of neuroblastoma. Lancet 1998, 351, 882-883.
23. Kato, J.; Kuwabara, Y.; Mitani, M.; Shinoda, N.; Sato, A.; et al. Expression of survivin in esophageal cancer: correlation with the prognosis and response to chemotherapy. Int. J. Cancer 2001, 95, 92-95.
24. Adida, C.; Haioun, C.; Gaulard, P.; Lepage, E.; Morel, P.; et al. Prognostic significance of survivin expression in diffuse large B-cell lymphomas. Blood 2000, 96, 1921-1925.
25. O'Connor, D.S.; Wall, N.R.; Porter, A.C.G.; Altieri, D.C. A p34 cdc2 survival checkpoint in cancer. Cancer Cell 2002, 2, 43-54.
26. Ansell, S.M.; Arendt, B.K.; Grote, D.M.; Jelinkek, D.F.; Novak, A.J.; et al. Inhibition of survivin expression suppresses the growth of aggressive non-Hodgkin's lymphoma. Leukemia 2004, 18, 616-623.
27. Fisker, N.; Westergaard, M.; Hansen, H.F.; Hansen, J.B. Survivin mRNA antagonists using locked nucleic acid, potential for molecular cancer therapy. Nucleosides Nucleotides Nucleic Acids 2007, 26, 1427-1430.
28. Li, F.; Ackermann, E.J.; Bennett, C.F.; Rothermel, A.L.; Plescia, J.; et al. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function. Nature Cell Biol. 1999, 1, 461-466.
29. Tolcher, A.W.;Mita, A.; Lewis, L.D.; Garrett, C.R.; Till, E.; et al. Antonia Phase I and pharmacokinetic study of YM155, a small-molecule inhibitor of survivin. J. Clin. Oncol. 2008, 26, 5198-5203.
30. Piescia, J.; Salz, W.; Xia, F.; Pennati, M.; Zaffaroni, N.; et al. Rational design of shepherdin, a novel anticancer agent. Cancer Cell 2005, 7, 457-468.
31. Talbot, D.C.; Davies, J.; Callies, S.; Andre, V.; Lahn, M.; et al. First human dose study evaluating safety and pharmacokinetics of LY2181308, an antisense oligonucleotide designed to inhibit survivin. J. Clin. Oncol. (ASCO Annual Meeting). 2008, 26 (May 20 suppl.), 3518 (Abstr.).
32. Nakagawa, K.; Satoh, T.; Okamoto, I.; Miyazaki, M.; Morinaga, R.; et al. Phase I study of YM155, a first-in-class survivin suppressant, in patients with advanced solid tumors in Japan. J. Clin. Oncol. (ASCO Annual Meeting). 2007, 25 (June 20 suppl.), 3536 (Abstr.).
33. Giaccone, G.; Zatloukal, P.; Roubec, J.; Floor, K.; Musil, J.; et al. Multicenter Phase II trial of YM155, a small-molecule suppressor of survivin, in patients with advanced, refractory, non-small-cell lung cancer. J. Clin. Oncol. 2009, 27, 4481-4486.
34. Singh, S.K.; Wengel, J. Universality of LNA-mediated high-affinity nucleic acid recognition. Chem. Commun. 1998, 1247-1248.
35. Koshkin, A.A.; Singh, S.K.; Nielsen, P.; Rajwanshi, V.K.; Kumar, R.; et al. LNA (locked nucleic acids): synthesis of the adenine, cytosine, guanine, 5-methylcytosine, thymine and uracil bicyclonucleoside monomers, oligomerisation, and unprecedented nucleic acid recognition. Tetrahedron 1998, 54, 3607-3630.
36. Greenberger, L.M.; Horak, I.D.; Filpula, D.; Sapra, P.; Westergaard, M.; et al. An RNA antagonist of hypoxia-inducible factor-1α EZN-2968, inhibits tumor cell growth. Mol Cancer Ther. 2008, 7, 3598-3608.
37. Hansen, J.B.; Fisker, N.;Westergaard, M., Kjaerulff, L.S.; Hansen, H.F.; et al. SPC3042: a proapoptotic survivin inhibitor. Mol Cancer Ther. 2008, 7, 2736-2745.
38. Jepsen, J.S.; Wengel, J. LNA-antisense rivals sRNA for gene silencing. Curr. Opin. Drug Discov. Devel. 2004, 7, 188-194.
39. Deguchi, M.; Shiraki, K.; Inoue, H.; Okano, H.; Ito, T.; et al. Expression of survivin during liver regeneration. Biochem. Biophys. Res. Commun. 2002, 297, 59-64.
40. Pennati, M.; Folini, M.; Zaffaroni, N. Targeting survivin in cancer therapy. Expert. Opin. Ther. Targets 2008, 12, 463-476.
41. Paduano, F.; Villa, R.; Pennati, M.; Folini, M.; Binda, M.; et al. Silencing of survivin gene by small interfering RNAs produces supra-additive growth suppression in combination with 17-allylamino- 17-demethoxygeldanamycin in human prostate cancer cells. Mol. Cancer Ther. 2006, 5, 179-186.
42. Olie, R.A.; Simões-Wüst, A.P.; Baumann, B.; Leech, S.H.; Fabbro, D.; et al. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy. Cancer Res. 2000, 60, 2805-2809.
43. Zhang, M.; Mukherjee, N.; Bermudez, R.S.; Latham, D.E.; Delaney, M.A.; et al. Adenovirus-mediated inhibition of survivin expression sensitizes human prostate cancer cells to paclitaxel in vitro and in vivo. Prostate 2005, 64, 293-302.
44. Sharma, H.; Sen, S.; Lo Muzio, L.; Mariggio, M.A.; Singh, N. Antisense-mediated down-modulation of anti-apoptotic proteins induces apoptosis and sensitizes head and neck squamous cell carcinoma cells to chemotherapy. Cancer Biol. Ther. 2005, 4, 720-727.
45. Cao, C.; Mu, Y.; Hallahan, D.E.; Lu, B. XIAP and survivin as therapeutic targets for radiation sensitization in preclinical models of lung cancer. Oncogene 2004, 23, 7047-7052.
46. Verhagen, A.M.; Ekert, P.G.; Pakusch, M.; Silke, J.; Connolly, L.M.; et al. Identification of DIABLO, a mammalian protein that promotes apoptosis by binding to and antagonizing IAP proteins. Cell 2000, 102, 43-53.
47. Kim, J.Y.; Chung, J.Y.; Lee, S.G.; Kim, Y.J.; Park, J.E.; et al. Nuclear interaction of Smac/DIABLO with survivin at G2/M arrest prompts docetaxel-induced apoptosis in DU145 prostate cancer cells. Biochem. Biophys. Res. Commun. 2006, 350, 949-954.
48. Meng, H.; Tanigawa, N.; Hao, C.Y.; Dai, D.J.; Lu, C.D.; et al. Chemoresponse to docetaxel correlates with expression of the survivin splicing variants in patients with gastric cancer. Hepatogastroenterology 2007, 54, 1934-1940.
49. Wang, T.; Wei, J.; Qian, X.; Ding, Y.; Yu, L.; et al. Gambogic acid, a potent inhibitor of survivin, reverses docetaxel resistance in gastric cancer cells. Cancer Lett. 2008, 262, 214-222.
50. Pennati, M.; Binda, M.; Colella, G.; Folini, M.; Citti, L.; et al. Radiosensitization of human melanoma cells by ribozyme-mediated inhibition of survivin expression. J. Invest. Dermatol. 2003, 120, 648-654.
51. Lu, B.; Mu, Y.; Cao, C.; Zeng, F.; Schneider, S.; et al. Survivin as a therapeutic target for radiation sensitization in lung cancer. Cancer Res. 2004, 64, 2840-2845.
52. Swayze, E.E., Siwkowski, A.M., Wanceiwicz, E.V., Migawa, M.T., Wyrzykiewicz, T.K., et al. Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nuc. Acid Res. 2007, 35, 687-700.